Apogee Therapeutics, Inc.
A clinical-stage biotechnology company developing antibody medicines for inflammatory and immune diseases such as atopic dermatitis, asthma, and COPD. Founded in 2022 as the first spinout from the Waltham, Massachusetts biotech Paragon Therapeutics, it engineers antibodies with longer half-lives so patients may need injections only every few months instead of weekly. The company went public on the Nasdaq in 2023.
Sold 1.75M
Granted 3.0K · Sold 280.0K
Granted 45.1K · Sold 102.1K
Sold 27.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fairmount Funds Management LLC +3 co-filersDirector · 1 transaction | — | 6.85M | — | — | 1.75M |
| Henderson Michael ThomasChief Executive Officer, Director · 33 transactions | -21.6% | 1.02M | 3.0K | — | 280.0K |
| Dambkowski CarlChief Medical Officer · 35 transactions | -24.1% | 179.2K | 45.1K | — | 102.1K |
| Henderson JaneChief Financial Officer · 22 transactions | -13.5% | 173.7K | — | — | 27.5K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -2.16M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.